JonesResearch analyst Justin Walsh initiated coverage of Serina Therapeutics (SER) with a Buy rating and $11 price target. Serina is a drug ...

The incidence of Parkinson disease was similar for the late use of CPAP (more than 2 years since OSA diagnosis) vs no use of CPAP. HealthDay News — Obstructive sleep apnea (OSA) is associated ...

Earlier this month, the FDA approved ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with ...

The company expects operating earnings (loss) between $(15) million and $10 million. Supernus also announced FDA approval for ONAPGO, its treatment for motor fluctuations in adults with advanced ...

ONAPGO™ (apomorphine hydrochloride), formerly known as SPN-830, approved by the U.S. Food and Drug Administration and will be launched in the second quarter of 2025. Full year 2025 guidance for total ...

The devices are being recalled due to an increased risk for permanently entering Safety Mode. HealthDay News — Boston Scientific has issued a recall of Accolade pacemaker devices, according to a ...

ONAPGO (apomorphine hydrochloride), formerly known as SPN-830, approved by the U.S. Food and Drug Administration and will be launched in the second quarter of 2025. Full year 2025 guidance for ...